Hubei Goto Biopharm Co.,Ltd.
SZSE:300966.SZ
21.06 (CNY) • At close October 26, 2023
Overview | Financials
Numbers are in millions (except for per share data and ratios) CNY.
| 2025 Q1 | 2024 Q4 | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 Q3 | 2022 Q2 | 2022 Q1 | 2021 Q4 | 2021 Q3 | 2021 Q2 | 2021 Q1 | 2020 Q4 | 2020 Q3 | 2020 Q2 | 2020 Q1 | 2019 Q4 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 138.92 | 171.206 | 131.568 | 111.255 | 122.228 | 181.361 | 117.217 | 148.398 | 119.423 | 157.748 | 178.476 | 147.896 | 120.451 | 144.935 | 143.271 | 160.852 | 141.827 | 148.625 | 117.424 | 165.14 | 36.929 | 111.599 |
| Cost of Revenue
| 105.467 | 117.625 | 120.231 | 100.868 | 95.866 | 144.92 | 88.284 | 112.693 | 95.382 | 125.326 | 141.999 | 111.448 | 87.993 | 105.838 | 107.408 | 117.025 | 104.704 | 112.649 | -157.507 | 126.492 | 31.014 | 0 |
| Gross Profit
| 33.453 | 53.581 | 11.337 | 10.387 | 26.362 | 36.441 | 28.933 | 35.705 | 24.042 | 32.422 | 36.477 | 36.448 | 32.458 | 39.097 | 35.863 | 43.827 | 37.124 | 35.976 | 274.93 | 38.647 | 5.915 | 111.599 |
| Gross Profit Ratio
| 0.241 | 0.313 | 0.086 | 0.093 | 0.216 | 0.201 | 0.247 | 0.241 | 0.201 | 0.206 | 0.204 | 0.246 | 0.269 | 0.27 | 0.25 | 0.272 | 0.262 | 0.242 | 2.341 | 0.234 | 0.16 | 1 |
| Reseach & Development Expenses
| 13.896 | 16.956 | 11.955 | 9.298 | 9.505 | 7.783 | 9.279 | 10.491 | 10.546 | 15.617 | 12.562 | 8.077 | 8.892 | 12.611 | 11.743 | 6.189 | 6.58 | 10.72 | 4.468 | 4.195 | 2.221 | 0 |
| General & Administrative Expenses
| 0 | -17.727 | 30.101 | 0.231 | 13.028 | -18.061 | 27.762 | -3.089 | 10.148 | 10.214 | 19.706 | -0.218 | 7.889 | -9.691 | 19.875 | 0.865 | 7.481 | 4.22 | 3.805 | -18.636 | 3.434 | 0 |
| Selling & Marketing Expenses
| 0 | -0.744 | 3.364 | 1.606 | 0.865 | 3.413 | 1.227 | 1.556 | 0.868 | 2.326 | 0.737 | 0.943 | 0.901 | 2.302 | 0.889 | 1.254 | 1.026 | 0.733 | 0.79 | 1.356 | 0.574 | 0 |
| SG&A
| 16.194 | -18.471 | 33.464 | 15.286 | 13.893 | -14.648 | 28.989 | -1.533 | 11.016 | 14.821 | 20.444 | 0.725 | 8.79 | -7.388 | 20.764 | 2.119 | 8.506 | 1.701 | 5.608 | -17.28 | 4.008 | 0 |
| Other Expenses
| 0 | 68.384 | -17.001 | 4.57 | -0.3 | -3.889 | 0.095 | -0.985 | 4.365 | 4.695 | 2.381 | 0.236 | 0.046 | 15.638 | 0.603 | 6.707 | 0.457 | -124.817 | -260.026 | 16.287 | -0.024 | -100.337 |
| Operating Expenses
| 30.09 | 68.763 | 28.418 | 20.014 | 21.484 | 17.901 | 22.376 | 21.399 | 21.679 | 35.133 | 23.28 | 17.812 | 17.258 | 29.395 | 19.999 | 18.927 | 15.152 | -124.817 | -260.026 | 11.106 | 6.031 | -100.337 |
| Operating Income
| 3.363 | -15.181 | -17.082 | -9.627 | 2.235 | 4.444 | 4.091 | 11.983 | -0.989 | -2.711 | 12.625 | 14.985 | 14.005 | 10.004 | 11.878 | 23.179 | 17.65 | 23.808 | 14.905 | 20.767 | -2.179 | 11.261 |
| Operating Income Ratio
| 0.024 | -0.089 | -0.13 | -0.087 | 0.018 | 0.025 | 0.035 | 0.081 | -0.008 | -0.017 | 0.071 | 0.101 | 0.116 | 0.069 | 0.083 | 0.144 | 0.124 | 0.16 | 0.127 | 0.126 | -0.059 | 0.101 |
| Total Other Income Expenses Net
| -7.542 | -4.025 | 2.096 | -4.02 | -0.3 | -3.889 | 0.095 | -0.985 | 4.365 | -3.052 | 2.381 | 0.236 | 0.046 | 15.638 | 0.603 | 6.707 | 0.457 | 0.662 | -0.484 | 2.788 | -0.024 | 2.697 |
| Income Before Tax
| -4.179 | -19.206 | -14.986 | -13.647 | 1.936 | 0.556 | 4.186 | 10.999 | 3.376 | -5.763 | 15.005 | 15.221 | 14.051 | 25.642 | 12.481 | 29.887 | 18.107 | 24.469 | 14.421 | 23.555 | -2.203 | 13.958 |
| Income Before Tax Ratio
| -0.03 | -0.112 | -0.114 | -0.123 | 0.016 | 0.003 | 0.036 | 0.074 | 0.028 | -0.037 | 0.084 | 0.103 | 0.117 | 0.177 | 0.087 | 0.186 | 0.128 | 0.165 | 0.123 | 0.143 | -0.06 | 0.125 |
| Income Tax Expense
| -3.62 | -4.078 | -5.345 | -3.499 | -0.957 | 0.642 | -0.558 | -1.982 | -0.275 | 5.896 | 2.293 | 1.328 | 1.274 | 1.403 | -0.5 | 4.17 | 2.979 | 2.471 | 1.812 | 2.67 | -1.987 | 0.497 |
| Net Income
| 1.082 | -13.429 | -9.044 | -8.666 | 3.547 | 0.221 | 5.312 | 13.448 | 4.024 | 0.288 | 12.937 | 13.936 | 13.044 | 24.265 | 13.022 | 25.766 | 15.277 | 21.998 | 12.608 | 20.885 | -2.203 | 13.461 |
| Net Income Ratio
| 0.008 | -0.078 | -0.069 | -0.078 | 0.029 | 0.001 | 0.045 | 0.091 | 0.034 | 0.002 | 0.072 | 0.094 | 0.108 | 0.167 | 0.091 | 0.16 | 0.108 | 0.148 | 0.107 | 0.126 | -0.06 | 0.121 |
| EPS
| 0.009 | -0.12 | -0.078 | -0.075 | 0.03 | 0.05 | 0.046 | 0.12 | 0.035 | 0.003 | 0.11 | 0.12 | 0.11 | 0.21 | 0.1 | 0.24 | 0.18 | 0.26 | 0.14 | 0.22 | -0.03 | 0 |
| EPS Diluted
| 0.009 | -0.12 | -0.078 | -0.075 | 0.03 | 0.05 | 0.046 | 0.12 | 0.035 | 0.003 | 0.11 | 0.11 | 0.11 | 0.21 | 0.1 | 0.24 | 0.18 | 0.26 | 0.14 | 0.22 | -0.03 | 0 |
| EBITDA
| 6.131 | 6.281 | -9.536 | -1.8 | 5.3 | 10.969 | 14.741 | 22.381 | 7.2 | 7.084 | 24.961 | 18.644 | 23.788 | 31.636 | 19.87 | 31.344 | 26.21 | -245.748 | 21.708 | 26.189 | 0.092 | -265.723 |
| EBITDA Ratio
| 0.044 | 0.037 | -0.072 | -0.016 | 0.043 | 0.06 | 0.126 | 0.151 | 0.06 | 0.045 | 0.14 | 0.126 | 0.197 | 0.218 | 0.139 | 0.195 | 0.185 | -1.653 | 0.185 | 0.159 | 0.002 | -2.381 |